Glycemic control and type 2 diabetes: CagriSema has the more extensive diabetes-specific trial data (REIMAGINE program), with demonstrated superiority over semaglutide alone on both HbA1c reduction and weight loss in T2D populations
This timeline highlights the highs and lows of innovation in obesity treatment: Early dangers: Drugs like DNP (1938) and Rainbow Pills (1968) were banned due to fatal side effects
Tesamorelins visceral-fat benefit reverses on discontinuation
A 2021 analysis published in Cardiovascular Diabetology found that semaglutide produced significant reductions in triglycerides and total cholesterol alongside its weight loss effects, with improvements correlating strongly with the degree of weight lost (Husain et al., Cardiovascular Diabetology, 2021, Tirzepatide and Cholesterol: Does the Dual Mechanism Help More For patients with significant lipid abnormalities, tirzepatide may offer an advantage over semaglutide
Variations should be submitted within six months of implementation
Be very clear about the unit of measurement (units, milligrams, milliliters) and how to draw it up in a syringe